1. Introduction {#s0005}
===============

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease. By 2050, 1 in 85 persons worldwide will be living with it, which will consume enormous social resources ([@b0040]). Failure of clinical trials in symptomatic patients has led to the belief that capturing brain changes and intervening at preclinical stages would more likely achieve therapeutic success ([@b0040], [@b0380]). Advances in neuroimaging biomarkers based on positron emission tomography (PET), structural magnetic resonance imaging (MRI) and cerebral spinal fluid (CSF) imaging methods ([@b0380], [@b0220]) provide evidence of AD pathophysiology in vivo. Structural MRI biomarkers are the mainstay of AD imaging research as well as clinical diagnosis ([@b0385], [@b0435]). MRI biomarkers include whole-brain ([@b0065], [@b0165], [@b0130]), entorhinal cortex ([@b0050], [@b0495], [@b0260]), hippocampus ([@b0320], [@b0295], [@b0365]; [@b0255]; [@b0340], [@b0145]), and temporal lobe volumes ([@b0200], [@b0120]), as well as ventricular expansion ([@b0210], [@b0410], [@b0445]). Ventricular expansion reflects diffuse brain atrophy ([@b0270], 2015). Owing to the high contrast between the CSF and surrounding brain tissue on T1-weighted images, the lateral ventricles can be measured more reliably than other brain structures ([@b0075]). These ventricular characteristics make ventricular expansion measures detectable at early and potentially preclinical AD stages ([@b0010], [@b0330]).

Ventricular expansion can be described by ventricular volume (VV) ([@b0460], [@b0335], [@b0275], [@b0120]) and ventricular surface morphometry ([@b0420], [@b0455], [@b0185], [@b0360]). Accelerating VV is associated with AD-related neuropathological progression and can be detected prior to clinically significant memory decline ([@b0460], [@b0010], [@b0330], [@b0275], [@b0120]). However, with VV alone cannot pinpoint the deformation details at the sub-regional level. We propose that ventricular morphology offers the possibility of being a more sensitive indicator of the details of subregional ventricular expansions which may differ between clinical subgroups.

Surface-based ventricular morphology biomarkers derived from ventricular anatomical models, such as radial distances (RD, distances from the medial core to each surface point) ([@b0420], [@b0155]) and tensor-based morphometry (TBM) ([@b0095], 2008; [@b0360]), are useful in overcoming partial volume effects and identifying detailed point-wise correlations between structural deformations and neurodegenerative progression of AD. RDs were estimated in order to track subfield morphology along the ventricular surface normal directions ([@b0420], [@b0445], [@b0010], [@b0185], [@b0335]). Deformations of ventricular subfields associated with cognitive decline can be located and visualized using a 3D RD field ([@b0420]). With the help of RD mapping, age related expansions of frontal and body/occipital horn portions of the lateral ventricles were found in cognitively unimpaired (CU) subjects ([@b0010]). Radial expansion of ventricular temporal horn surfaces was faster in AD than in CU subjects ([@b0420]).

Surface TBM ([@b0415]; [@b0095], 2008) is able to quantify brain deformations within surfaces. It has been applied to detect regional differences in brain surface morphometry between clinical groups ([@b0360]). However, TBM is limited in its accuracy of modeling relatively small-scale structures ([@b0070]). To overcome this limitation, we developed the multivariate TBM (mTBM) method and applied it to HIV/AIDS subjects and healthy controls ([@b0455]). This method gave better effect sizes for detecting ventricular morphometry differences than other TBM-based methods, including analysis of the Jacobian determinant, the largest and smallest eigenvalues of the surface metric, and the pair of eigenvalues of the Jacobian matrix ([@b0455], 2011). To comprehensively capture deformations along the surface normal directions and within surfaces, we developed multivariate morphometry statistics (MMS) combining mTBM and RD to detect brain abnormalities associated with neurodegenerative diseases ([@b0145], [@b0355], [@b0360], [@b0445], [@b0255]). Our previous studies ([@b0455], 2011) demonstrated that surface-based MMS gained improved statistical power compared to other TBM-based methods.

Few studies have revealed ventricular morphometry abnormalities of CU progressors who imminently progressed to clinically significant memory decline. Previous studies of ventricular morphometric modeling ([@b0420], [@b0160], [@b0070], [@b0445], [@b0010], [@b0335]) mapped only part of anatomical ventricular surfaces, with coverage of inferior or posterior horns being incomplete. In this work, we propose a complete ventricular morphometry analysis system (VMAS), which is based on MMS proposed by our previous methods ([@b0455], 2011), but includes an automated ventricular segmentation method ([@b0490]), together with an efficient morphometric expansion/atrophy visualization analysis module ([@b0480], [@b0145]). The proposed VMAS can capture a whole connected 3D ventricular surface characteristic as well as subregional deformations. We hypothesize that our VMAS will detect and visualize ventricular morphometry abnormalities of CU progressors who subsequently progressed to clinically significant memory decline within 2 years post-baseline, compared to CU non-progressors. We test and validate this hypothesis in two independent CU cohorts, using cross-sectional structural MRI and the VMAS to compute bilateral ventricular morphometries and visualize ventricular morphometric expansions at subregional levels that are related to memory decline.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

Two cohorts were used for testing the performance of the VMAS. The first is the *Arizona APOE cohort*: 38 subjects from an imaged sub-cohort of 280 drawn from the 26-year longitudinal *Arizona APOE* cohort study ([@b0060], [@b0055]). The subjects selection met the criterion adopted in our prior work ([@b0395]): CU progressors had both MRI and FDG PET data while still cognitively unimpaired at the epoch approximately 2 years prior to progression to clinically memory impairment; CU non-progressors had at least 4 years over which they remained cognitively unimpaired and matched to progressors for sex, age, education and APOE allele dose. Then we found 18 CU progressors and matched 20 CU non-progressors in the Arizona APOE cohort. Among these 18 progressors, sixteen were eventually diagnosed with amnestic mild cognitive impairment (aMCI), one with amnestic and visuospatial MCI, and one with mild stage AD dementia. AMCI diagnosis fulfilled published criteria ([@b0005], [@b0280]). The *Arizona APOE* cohort was approved by the Mayo Clinic and Banner Good Samaritan Institutional Review Boards. After a complete description of the study was given to the subjects, written informed consent was obtained.

The second cohort is drawn from the *Alzheimer's Disease Neuroimaging Initiative (ADNI) database* (adni.loni.usc.edu). ADNI is the result of efforts of many co‐investigators from a broad range of academic institutions and private corporations. Subjects have been recruited from over 50 sites across the U.S. and Canada. The primary goal of ADNI is to test whether biological markers, such as serial MRI and PET, combined with clinical and neuropsychological assessments, can measure the progression of MCI and early AD. Subjects originally recruited for ADNI‐1 and ADNI‐GO had the option to be followed in ADNI‐2. For up‐to‐date information, see www.adni-info.org. In this study, study participants were drawn from ADNI-1 data base utilizing the same inclusion criteria described above for the Arizona APOE cohort. From ADNI-1, we found 18 participants who developed clinically significant memory impairment, i.e. aMCI, in approximately 2 years and 26 age, sex, education and APOE-matched non-progressors remained cognitively unimpaired for at least 4 years.

2.2. Overview of VMAS {#s0020}
---------------------

The current work proposes the VMAS to study the ventricular abnormalities of CU progressors compared to CU non-progressors during the preclinical stage, as shown in [Fig. 1](#f0005){ref-type="fig"}. This system consists of ventricular segmentation, ventricular surface reconstruction, and ventricular surface MMS analysis.Fig. 1An illustration of the novel surface-based ventricular morphometry analysis system. First, individual MRI scans (a) were linearly registered into a standard space (MNI152) (b). Second, the registered images were segmented into three brain tissue types (the gray matter, white matter, and CSF); a group-wise CSF template was created from all individual CSF masks, and the group-wise ventricular template were subsequently obtained from the group-wise CSF template (c). Third, binary ventricular masks were segmented and extracted, then ventricular surface meshes were constructed and smoothed (d). Fourth, the whole ventricular surface was cut into three sub-structures (e). Fifth, each sub-ventricular surface was conformally mapped to a rectangle in the parameter domain, and vertex-wise multivariate morphometry statistics (MMS) were estimated on these mapped surfaces (f). Last, the morphometric variations of ventricular surfaces between groups were evaluated, and significantly different subregions were shown in the form of a *p*-map (non-blue regions: *p* \< 0.05) of the comparison analysis (g). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

First, individual MRI scans were linearly registered into a standard space (MNI152) by using a FSL software package ([@b0230]). Second, the registered images were segmented into three brain tissue types (the gray matter, white matter and cerebrospinal fluid (CSF)) using a modified Gaussian mixture model (SPM8 packages, <http://www.fil.ion.ucl.ac.uk/spm/>). A group-wise CSF template was then created by applying the geodesic shooting algorithm ([@b0025]), which learns the minimal deformation from all of the individual CSF segmentations to an averaged template. Third, based on this averaged CSF template, we extracted the ventricular structure by mapping a probability ventricular mask, i.e., the automatic lateral ventricle delIneatioN (ALVIN) binary mask ([@b0240]), onto the template. A binary ventricular template of our dataset was formed, and ventricular boundaries were visually inspected. The deformation matrices from the estimation of group-wise CSF template were then used to wrap the ventricular template back to the individual space. With a topology preserving level-set method ([@b0190]) and marching cubes algorithm ([@b0265]), ventricular surface meshes were reconstructed according to the shape of each individual ventricular volumetric template. Before geometric analysis of these reconstructed ventricular surfaces, we applied a two-step mesh smoothing method ([@b0485]) to remove noise and topologically irregular structures. Fourth, due to the naturally occurring 3-horn shape, the whole ventricular surface was cut into three sub-structures by the holomorphic 1-forms segmentation method ([@b0455]). Fifth, sub-ventricular surfaces were independently registered to standard regular maps, and vertex-wise MMS of deformation fields of the surface registration were estimated on these registered surfaces ([@b0445], [@b0490]). These MMS can be regarded as the vertex-wise geometry features. Finally, we conducted vertex-wise statistical analysis of MMS to compare ventricular morphometry differences between CU progressors and CU non-progressors. Expansive directions of these significant ventricular subregions were analyzed using RD statistics and mTBM statistics separately. Additionally, we also make effect size analysis of VV and our proposed MMS measures. The entire ventricular morphometry analysis pipeline is publicly available at <http://gsl.lab.asu.edu/software/ventricle/>.

### 2.2.1. MRI registration and ventricle segmentation {#s0025}

With the FSL software package ([@b0230]), T1 MRI images were linearly registered into a standard space (MNI152) to remove the effect of brain size. Then the registered images were parcellated into three brain tissue types (the gray matter, white matter, and CSF) using a modified Guassian mixture model (SPM8 packages, <http://www.fil.ion.ucl.ac.uk/spm/>) to estimate the tissue type probability of each voxel based on a prior probability map. After doing tissue segmentation for all subjects, we estimated a group-wise CSF template through the geodesic shooting algorithm ([@b0025]), which introduced the minimal distortion of mappings from the source CSF image $f(x)$ to the estimated averaged CSF template $\mu(x)$, e.g., $f\left( {\varphi_{1}\left( x \right)} \right)\rightarrow\mu\left( x \right)$. Essentially, in the first step, the initial CSF template was set as the mean shape and intensity of the individual CSF tissue images and updated iteratively. During each iteration, the objective function is minimized by a proper initial velocity field υ~0~ and the final object function is expressed as:$$E = \frac{1}{2}{{\| L}v_{0}\|}^{2} + \frac{1}{2\sigma^{2}}\int_{x \in \omega}\left| {J_{1}^{\varphi}\left( x \right)} \right|{(f\left( {\varphi_{1}\left( x \right)} \right) - \mu\left( x \right))}^{2}dx$$where the first term measures the image distortion during the mapping while the second term evaluates accuracy of the mapping for all voxels. Here, *φ~1~* is a forward diffeomorphism from subject to template parameterized by υ~0~ and $J_{1}^{\varphi}\left( x \right)$ is the corresponding Jacobin tensor. *L* in the first term is a linear differential operator which can be understood as a regularization of the deformation and is defined as:$${{\| L}v_{0}\|}^{2} = \int_{x \in \omega}{(\frac{\lambda_{1}}{4}{{\| Dv +}\left( {Dv} \right)^{T}\|}^{2} + \lambda_{2}tr\left( {Dv} \right)^{2} + \lambda_{3}{\| v\|}^{2})}dx$$

The term associated with $\lambda_{1}$ controls the image shearing and stretching. The term weighted by $\lambda_{2}$ controls local volume expansion and contraction. The last term with $\lambda_{3}$ denotes the absolute displacement of voxels. Details of optimizing Eq. [(1)](#e0005){ref-type="disp-formula"} can be found in ([@b0025]). A group average of all deformed shapes is computed after each round of iteration and set as the template for the next iteration. Eventually, a stable result of CSF template is derived after several iterations, e.g. typically 5 to 6 iterations, and is regarded as the group-wise CSF template. As a part of the CSF, the group-wise ventricular template was subsequently obtained by mapping a probability ventricular mask onto the group-wise CSF template. In this study, the Automatic Lateral Ventricle delIneatioN (ALVIN ([@b0240])) binary mask was applied to exclude CSF tissues outside the ventricular masks. Once the group-wise ventricular template is extracted, with the help of deformation fields from the previous optimization process, we inversed the image registration and segmented the individual ventricular structures from the original 3D brain images.

### 2.2.2. Ventricular surface reconstruction and registration {#s0030}

Based on segmented binary volumetric masks, we extracted ventricular boundaries with a topology preserving level-set method ([@b0190]) and constructed triangular surface meshes with marching cubes algorithm ([@b0265]). Later, the surfaces were further smoothed using a two-step mesh smoothing method, i.e., combination of "progressive meshes" and Loop subdivision, which had proved to be feature-preserving while effectively reducing the noise and partial volume effect ([@b0485]).

We needed to parameterize the ventricular surface with 2D intrinsic geometry properties ([@b0420], [@b0445]). Since a ventricular surface has a complex geometric structure, i.e., a "multiple-arm" shape, we cut and modeled the whole ventricular surface into three horns using the holomorphic 1-forms method ([@b0440], 2010). Three horns, including anterior horn, posterior horn and inferior horn, were automatically located and separated from each ventricular surface. This holomorphic 1-forms method induced conformal grids which demonstrated the angle preserving property on the tube-like subregional surfaces ([@b0440], 2010). Basically, we first followed our previous work ([@b0360]) to locate a singularity point (zero point) which is a geometric landmark of ventricle, and is structurally consistent across subjects. Based on this landmark, a Euclidean conformal parameterization was computed resulting in the 3-horn decomposition. Next, constrained harmonic maps were computed to respectively register each of the ventricular sub-surfaces to a standard map. The harmonic mapping τ can be expressed as below:$$\tau^{{^\circ}}\tau_{1}\left( S_{1} \right) = \tau_{2}\left( S_{2} \right),\tau^{{^\circ}}\tau_{1}\left( {\partial S}_{1} \right) = \tau_{2}\left( {\partial S}_{2} \right),\delta\tau = 0$$

Here *τ*~*1*~ and *τ*~*2*~ are conformal parameterizations that respectively map surface *S*~*1*~ and *S*~*2*~ to a square disc R^2^. The map ϕ from surface *S*~*1*~ to surface *S*~*2*~ can be obtained by$\phi = \tau_{1}{^\circ}\tau{^\circ}\tau_{2}^{- 1}$.

### 2.2.3. Ventricular surface multivariate morphometry statistics (MMS) {#s0035}

Three ventricular horns are tube-like shapes. To improve morphometric analysis, our previous study ([@b0445]) proposed MMS measure to capture differences along all possible directions. MMS consists of RD and mTBM. The RD describes morphometric changes along the surface normal direction ([@b0315], [@b0420], b). The mTBM captures deformations within surfaces such as rotation, dilation, and shears with surfaces that are perpendicular to the surface normal direction ([@b0250], [@b0455]). After ventricular surface registration and conformal parameterization, RD was defined as the distance from each parametric surface point to the center of 3D positions of the *iso*-u curves (red curves illustrated on ventricular surfaces of [Fig. 1](#f0005){ref-type="fig"}) in the parameter domain ([@b0445]).

We calculated the vertex-wise surface mTBMs, which can be represented as a 3 × 1 feature. MTBM is a "Log-Euclidean metric" ([@b0020]) on the set of deformation tensors *S*, i.e., a 3 × 1 positive definite matrix (*log(S)*). More specifically, the deformation tensors *S* is computed as $S = {(J^{T}J)}^{1/2}$, where *J* is the Jacobian matrix ([@b0455]). Suppose there are two surfaces $A = \lbrack a_{1},a_{2},a_{3}\rbrack$ and$B = \lbrack b_{1},b_{2},b_{3}\rbrack$, which are isometrically embedded on the Euclidean space, the discrete derivative map *J* from *A* to *B* is approximated as$J = {\lbrack a_{3} - a_{1},a_{2} - a_{1}\rbrack}{\lbrack b_{3} - b_{1},b_{2} - b_{1}\rbrack}^{- 1}$. Eventually, TBM is defined as$\sqrt{detJ}$, where $detJ$ is the determinant of Jacobian matrix and mTBM can be expressed as $log\sqrt{JJ^{T}}$. Finally, MMS for each vertex on the individual ventricular surface was formed as a 4 × 1 vector by combining the mTBM and RD statistics. That is, each individual ventricle can be represented as a *W* × 4 feature matrix, *W* is the vertices number of a ventricle surface.

### 2.2.4. Ventricular surface MMS smoothing {#s0040}

The mesh smoothing process introduced in subsection 2.2.2 is used to reduce the noise from image acquisition, segmentation, and partial volume effects in surface reconstruction ([@b0365]). The remaining noise and noise introduced in subsequent processes still affect the signal noise ratio (SNR) in the surface features and in the final statistical analysis. Thus, the heat kernel smoothing algorithm ([@b0090], [@b0360]) was introduced to refine the ventricular surface features. Referring to our previous work ([@b0360]), key parameters of the heat kernel smoothing algorithm were set as: smoothing parameter σ = 1 and number of iterations m = 10.

### 2.2.5. Group-wise ventricular surface morphometry analysis {#s0045}

The Hotelling's *T^2^* test ([@b0195], [@b0045]) was performed to evaluate the morphometric variations of the smoothed ventricular surfaces between CU progressors and non-progressors on each vertex. Statistical results were corrected for multiple comparisons using the permutation test ([@b0455]). Basically, we calculated the Mahalanobis distance based on the true group labels first. Then we randomly assigned the object surfaces into two groups which had the same number of subjects as in the true group and re-computed the group distance on each surface point. This process repeated 10,000 times with the outcome of 10,000 permutation values on each vertex. A probability (uncorrected *p* value) on each surface point was computed as a ratio, i.e., percentage of permutations when the estimated permutation values was greater than the true group *t* value. After that, given a pre-defined statistical threshold, i.e. *p* \< 0.05, we defined a feature to be the number of surface points with uncorrected *p* value lower than this threshold. The feature could be regarded as a real effect in the true experiment, and by comparing it to the features derived from the random groupings, we obtained a ratio that stood for the fraction of the time an effect of similar or greater magnitude to the real effect occurred in the random assignments. This ratio, the *overall (corrected) significance*, provided a global significance level of the map.

After we calculated the significant variations on the ventricular surface, we could apply directional analysis ([@b0480], [@b0145]) to study the correspondence between VV enlargement and ventricular morphometry expansion. The direction (atrophy or expansion) of group differences were analyzed along the surface normal direction and within surfaces at each surface point. We mapped RD and the determinant of the Jacobian matrix (*detJ*), i.e., the TBM ([@b0135], [@b0415], [@b0085]), at each significant surface vertex *k* of subject group 1 (CU progressors) and group 2 (CU non-progressors) in a difference map according to the following formula:$$R^{k} = \frac{\sum_{i}^{N_{1}}\mathit{Ver}_{1i}^{k}}{N_{1}} - \frac{\sum_{j}^{N_{2}}\mathit{Ver}_{2j}^{k}}{N_{2}}$$where $\mathit{Ver}_{1i}^{k}$ and $\mathit{Ver}_{2j}^{k}$ are the RD or *detJ* for *i*th subject in group 1 and *j*th in group 2, and $N_{1}$ and $N_{2}$ are the number of subjects in each group. Under the significant level (*p* \< 0.05), $R^{k} > 0$ indicates that CU progressors have an enlargement along the normal direction or within surfaces at a given surface point *k* contrast to CU non-progressors$;R^{k} < 0$ indicates that CU progressors have an atrophy along the normal direction or within surfaces at a given surface point *k* in contrast to CU non-progressors.

### 2.2.6. Effect size analysis {#s0050}

The effect size method, Cohen's d ([@b0110]), can determine the degree of ventricular deformations in CU progressors compared to CU non-progressors. Hedge's g is an alternative of Cohen's D where different sample sizes exist, so we use Hedge's g (Eq. [(5)](#e0025){ref-type="disp-formula"}) to calculate the effect sizes of ventricular volume measures ([@b0180]), where $m_{1}$ and $m_{2}$ are the mean VV values of CD progressor and non-progressor groups respectively, $n_{1}$ and $n_{2}$ are the sample sizes of each group, $\mathit{SD}_{1}$ and $\mathit{SD}_{2}$ are the standard deviations of each group. The Hedge's g and Cohen's d statistics can be interpreted by levels: low effect (\<0.5), medium effect (\<0.8) and high effect (\>0.8) ([@b0170]).$$\mathit{Hedges}^{\text{'}}g = \frac{m_{1} - m_{2}}{\mathit{SD}_{\mathit{pooled}}^{\ast}},\mathit{SD}_{\mathit{pooled}}^{\ast} = \sqrt{\frac{\left( {n_{1} - 1} \right)\mathit{SD}_{1}^{2} + \left( {n_{2} - 1} \right)\mathit{SD}_{2}^{2}}{n_{1} + n_{2} - 2}}$$

MMS is a multivariate measure. The above effect size methods cannot be directly applied. The study of ([@b0350]) pointed out that Mahalanobis distance can provide a multivariate measure of effect. Within the significant deformation subregions, we make vertex-wise effect size statistics using Mahalanobis distance (Eq. [(6)](#e0030){ref-type="disp-formula"}), where $M_{1}$ and $M_{2}$ are the mean $4 \times 1$ MMS vector per ventricular surface vertex of CD progressor and non-progressor groups respectively, $S$ is their corresponding $4 \times 4$ covariance matrix. The Mahalanobis distance $D^{2}$ is the multivariate analogue of the univariate Cohen's d effect size, it can be interpreted by levels: small effect (=0.25), medium effect (=0.5) and high effect (\>=1) ([@b0390]).$$D^{2} = \left( {M_{1} - M_{2}} \right)^{T}S^{- 1}\left( {M_{1} - M_{2}} \right)$$

3. Results {#s0055}
==========

3.1. Study samples {#s0060}
------------------

Demographic information for the *Arizona APOE* cohort and *ADNI* cohort are summarized in [Table 1](#t0005){ref-type="table"}. Within each cohort, group differences of gender and APOE-ε4 genotype were estimated using chi-square tests, group differences of age and education were calculated by *t*-tests ([@b0125], [@b0145]). Inferential analysis demonstrated that the CU progressors and non-progressors have no significant differences on sex, age, education, and relevant APOE genotype.Table 1Demographic characteristics of *Arizona APOE* and *ADNI* cohorts at the time of baseline MRI scan.CU progressorsCU non-progressors*P*-Value*Arizona APOE* cohortBaseline sample sizen = 18n = 20Sex (M/F)7/117/130.80ε4 Genotype (N)13:03:0213:04:030.89% (HM:HT:NC)(72:17:11)(65:20:15)Age68.75 ± 4.6566.76 ± 3.290.13Education16.44 ± 1.6915.50 ± 3.330.29*ADNI* cohortBaseline sample sizen = 18n = 26Sex (M/F)15/316/100.11ε4 Genotype (N)(HM:HT:NC)0:07:110:06:200.26Age79.64 ± 4.1677.60 ± 3.910.10Education15.83 ± 3.0716.62 ± 2.550.36[^2]

3.2. Ventricular volume {#s0065}
-----------------------

Since VV measure is an effective measurement for studying AD pathological progress (Jack Jr. et al. 2008; [@b0325], [@b0375]), we conducted a VV comparison analysis of CU progressors vs. non-progressors using *t*-test on both cohorts. Similar to prior approaches used to compute brain volume for AD diagnosis ([@b0305], [@b0345], [@b0105], [@b0100], [@b0295]), the VVs were computed on the smoothed ventricular structures after they were linearly registered to the MNI imaging space ([@b0300], [@b0370]). [Table 2](#t0010){ref-type="table"} shows the volume means (standard deviations) of the CU progressors and non-progressors, at baseline, prior to clinically significant memory decline in the CU progressors. In both cohorts, bilateral VVs of the CU progressors were significantly larger than the non-progressors. Therefore, abnormal enlargements in VVs of CU progressors can be detected two years before a clinically significant memory decline.Table 2Bilateral ventricular volumes of CU progressors and non-progressors at baseline.LV volume (cm^3^) (mean ± SD)*p*-valueRV_volume (cm^3^) (mean ± SD)*p*-value*Arizona APOE* cohortCU progressors53.6 ± 15.00.01751.8 ± 18.20.047CU non-progressors42.7 ± 11.841.5 ± 10.9*ADNI* cohortCU progressors48.6 ± 10.80.01847.3 ± 11.00.013CU non-progressors41.2 ± 8.639.2 ± 9.5[^3]

3.3. Ventricular morphometry {#s0070}
----------------------------

After ventricular abnormalities of CU progressors were detected using the VV measure, we expected to further reveal abnormal subregional expansions on ventricular surfaces of the CU progressors with VMAS. [Fig. 2](#f0010){ref-type="fig"} shows the *p*-maps of CU progressors vs. non-progressors at particular regions of the bilateral ventricles. Non-blue colors show vertices with statistical differences at the nominal 0.05 level, uncorrected for multiple comparisons. In the two independent cohorts, we observed consistent deformation patterns of ventricular subregions in the CU progressors, which were mainly on the anterior horn of both ventricles and more on the left ventricle than the right side. We then re-ran analyses with a permutation test to correct for multiple comparisons. In the *Arizona APOE* cohort (20 CU non-progressors vs. 18 CU progressors), we found overall significant morphometric differences on the left ventricle (LV, *p* = 0.01) and the right ventricle (RV, *p* = 0.03), as shown in [Fig. 2](#f0010){ref-type="fig"}(a). In the *ADNI* cohort (26 CU non-progressors vs. 18 CU progressors), we also found overall significant morphometric differences on the LV (*p* = 0.01) and RV (*p* = 0.02), as shown in [Fig. 2](#f0010){ref-type="fig"}(b).Fig. 2Subregional differences on the ventricular surfaces of CU progressors and non-progressors in two independent cohorts. Color indicates level of *p* value, uncorrected, for group comparisons at particular regions. When a permutation test was run to correct for multiple comparisons, for the *Arizona APOE* cohort (a) there were significantly overall morphometric differences between the CU non-progressors and progressors on the left (*p* = 0.01) and right (*p* = 0.03) ventricles; a similar effect was found in the *ADNI* cohort (b, left ventricle, *p* = 0.01, and right ventricle, *p* = 0.02).

3.4. Directional ventricular morphometry {#s0075}
----------------------------------------

Additionally, we analyzed the directions of surface deformations using RD and mTBM metrics. Consistent with VV enlargement results, these significantly abnormal ventricular regions of CU progressors are expansive along the normal direction or within surfaces compared to CU non-progressors in both the *Arizona APOE* and *ADNI* cohorts. The studied regions (non-blue areas) in [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"} are the statistically significant regions from group difference studies shown in [Fig. 2](#f0010){ref-type="fig"}(a) and (b). They are identified by using the proposed statistics, i.e. MMS, the combination of RD and mTBM. Here, we extend our observation in a way to emphasize the deformation directions. It is worth noting that the enhanced statistical power gained by additional directional elements in mTBM cannot be visualized by TBM. Even so, within the detected significant regions, RD and mTBM convey a rather similar expansive pattern in most parts, indicated by the fact that most of the red regions are overlapped. Few inverse associations in some (green) regions presented that these regions are atrophy ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}a) measured by RD but expansive ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}b) measured by TBM, and vice versa. The similarity between panels (a) and (b) in [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"} helps demonstrate the largely consistent observations from RD and surface TBM, i.e., the expansion along the normal direction (measured by RD) may also result in surface area expansive (measured by TBM). In [Fig. 4](#f0020){ref-type="fig"}, these findings were reproduced in ADNI cohort. These directional analyses demonstrated that RD may be a good complement to mTBM. MMS may illustrate the ventricular subregional deformations comprehensively.Fig. 3Directional analysis in non-blue regions (*p* \< 0.05) of CU progressors compared to non-progressors in *Arizona APOE* cohort. Red and green colors highlight vertices with significant ventricular expansions and atrophies along the surface normal directions (a) and within surfaces (b), respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4Directional analysis in non-blue regions (*p* \< 0.05) of CU progressors compared to non-progressors in *ADNI* cohort. Red and green colors highlight vertices with significant ventricular expansions and atrophies along the surface normal directions (a) and within surfaces (b), respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

3.5. Cumulative distribution analysis of the ventricular morphometry {#s0080}
--------------------------------------------------------------------

To further validate which lateral ventricle is more sensitive to the progress of AD pathology, the cumulative distribution functions (CDF) of the contrast *p*-values are plotted against the corresponding *p*-value that would be expected, under the null hypothesis of no group difference, as has been used in our prior work ([@b0455], 2011, 2013; [@b0370], 2014; [@b0145]). For null distributions, the CDF of *p*-values is expected to fall approximately along the line (y = x) ([@b0455]). Greater effect sizes are represented by larger deviations (the theory of false discovery rates gives the formulation for thresholds that control false positives at a known rate).

[Fig. 5](#f0025){ref-type="fig"} shows CDF of the p-values from bilateral ventricular morphometry comparisons of CU progressors vs. CU non-progressors in the two cohorts, respectively, plotted against the expected p-values under the null hypothesis (blue dashed line) of no group differences among the comparisons. The deviations of the statistics from the null distribution generally increased from RV abnormalities (green line) to LV abnormalities (red line) in CU subjects, suggesting that the LV has greater effect sizes to track AD pathologic progress in the preclinical stage compared to the RV.Fig. 5Cumulative distribution functions of the *p*-values from bilateral ventricular morphometry comparisons of CU progressors vs. non-progressors in two independent cohorts, plotted against the expected *p*-values under the null hypothesis (y = x, blue dash line) of no group differences among the comparisons. In the false discovery rate methods, any cumulative distribution plot that rises steeply is a sign of a significant signal being detected, with curves that rise faster denoting higher effect sizes. The steep rise of the cumulative plot relative to *p*-values that would be expected by chance can be used to compare the detection sensitivity of different statistics derived from the same data. The deviations of the statistics from the null distribution generally increased from right ventricle (RV) abnormalities (green line) to left ventricle (LV) abnormalities (red line) in the CU subjects, suggesting that the LV is more sensitive to AD pathologic progress in the preclinical stage compared to the RV. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

3.6. Effect sizes of VV and MMS measures {#s0085}
----------------------------------------

Effect sizes of VV analysis is calculated using Eq. [(5)](#e0025){ref-type="disp-formula"}. [Table 3](#t0015){ref-type="table"} shows the effect sizes of bilateral VV comparisons on two cohorts. VV measure has medium effect sizes (\>0.5 and \<=0.8) in distinguishing CU progressors and non-progressors.Table 3Effect sizes of ventricular volumes of CU progressors and non-progressors at baseline.LV volume effect sizeRV volume effect size*Arizona APOE* cohortCU progressors vs. CU non-progressors0.7380.700*ADNI* cohortCU progressors vs. CU non-progressors0.7740.800[^4]

Within the significant deformation subregions, effect sizes of MMS comparisons are calculated using Eq. [(6)](#e0030){ref-type="disp-formula"}. [Fig. 6](#f0030){ref-type="fig"} shows the vertex-wise effect size maps of bilateral MMS comparisons on two cohorts. Most of the effect sizes are\>0.8 (red regions). Yellow subregions represent large ($D^{2}$=\>1) effect sizes. These effect size results demonstrate that ventricular MMS has added value compared to VV.Fig. 6Illustrations of the effect size maps of CU progressors compared to non-progressors in *Arizona APOE cohort* and *ADNI* cohort.

4. Discussion {#s0090}
=============

After analyzing cross-sectional structural MRI images of two independent CU cohorts, our results consistently show that CU progressors have larger ventricular expansions mainly in the anterior horns (greater on the left ventricle) compared to CU non-progressors. These results support our hypothesis that our completely automated VMAS can detect ventricular morphometry abnormalities of CU progressors compared to CU non-progressors prior to clinically significant memory decline. These ventricular morphometric abnormalities did not only mirror VV estimates in two independent cohorts, but they also detailed the abnormal subfields caused by AD. To our knowledge, this is the first study to use the surface-based ventricular morphometry approach to successfully detect ventricular subregional abnormalities of CU progressors two years before their progression to clinically significant memory decline. Our study is among the first to describe a completely automated VMAS capable of generating a whole connected 3D ventricular shape model.

4.1. Ventricular volumetric analysis in cognitively unimpaired subjects {#s0095}
-----------------------------------------------------------------------

Lateral ventricular boundaries (CSF/brain) have high contrast from adjacent tissue, which facilitates ventricular segmentation in MRI scans, so that ventricular measures may be the most reliable and robust for studying AD pathophysiologic progression ([@b0160], [@b0070], [@b0270], 2015). Previous studies ([@b0465], [@b0275], [@b0120]) demonstrated VV measures can detect ventricular enlargements associated with AD prior to clinically significant memory decline. Here, we estimated the VV differences between CU progressors and non-progressors in two independently CU cohorts. Our results are consistent with those of previous studies ([@b0460], [@b0120]), showing that abnormal ventricular expansions are prior to future clinically cognitive decline in CU progressors. This knowledge will facilitate subject enrollment, in a timely fashion, in clinical trials aimed at prevention of AD process ([@b0225], [@b0460], [@b0010], [@b0330], [@b0275], [@b0120]). Additionally, our results from two cognitively unimpaired cohorts indicate the left ventricle volume is larger than the right, so we infer that the left ventricle is more severely affected than the right during the pre-clinical stage. Consistent with this, others have found a larger left VV in MCI patients compared to CUs ([@b0010], [@b0275]).

4.2. Ventricular shape modeling in cognitively unimpaired subjects {#s0100}
------------------------------------------------------------------

It is difficult to parameterize the ventricular surface because of its 'multiple-arm' structural property ([@b0455]). To capture more deformation details of the ventricular structure, some studies developed surface-based ventricular morphometry analysis methods based on RD measures to track deformations roughly along the surface normal direction, and found anterior and body/posterior horn portions of the lateral ventricles had age-related expansions ([@b0420], [@b0010]). Other studies developed TBM-based methods to track ventricular deformations within surfaces ([@b0430], [@b0205], [@b0360]), the study of ([@b0360]) applied the TBM biomarker to distinguish ventricular shapes of 71 MCI converters from 62 MCI stable controls, and these group different regions close to the temporal lobe and posterior cingulate. Our previous study ([@b0445]) indicated mTBM provided better effect sizes for detecting ventricular morphometric differences than TBM measure in 804 subjects (184 CE, 391 MCI and 229 CU). The proposed VMAS applied MMS including RD and mTBM to detect abnormal deformations along the ventricular surface normal directions and within the ventricular surfaces of CU progressors, which have not been extensively studied. Our results demonstrated that pre-symptomatic CU progressors have more expansive ventricular anterior subfields, and the left ventricle is more prominent in this regard than the right.

To our knowledge, it is the first study to use the surface-based ventricular morphometry approach to successfully identify ventricular abnormalities in pre-symptomatic CU progressors. Several brain imaging-based AD studies ([@b0425], [@b0400], [@b0160], [@b0080], [@b0290], [@b0015], [@b0115]) demonstrated that surface-based biomarkers outperform volume measures. Regional brain deformations associated with AD involve wide range of brain structures, the well-known structures are hippocampus, ventricle and cortical thickness ([@b0165], [@b0130], [@b0310], [@b0325], [@b0375]). Together with this work, we developed a series of surface-based biomarkers of different brain structures for AD research ([@b0455], 2011; [@b0150], [@b0145]). Our latest work ([@b0140]) has indicated that combining these three biomarkers could empower the prediction of AD progression. The current work also lays down a solid foundation for our future comprehensive AD structural biomarkers in the preclinical stage. Additionally, previous studies of ventricular morphometric modeling ([@b0010], [@b0070], [@b0160], [@b0335], [@b0420], [@b0445], [@b0450]) mapped only part of anatomical ventricular surfaces, with coverage of inferior or posterior horns being incomplete. This work proposes an automated ventricular surface segmentation method which can generate a whole connected 3D ventricular model, which benefits tracking more ventricular subregional information.

4.3. Limitations and future work {#s0105}
--------------------------------

Despite the promising results are obtained by applying our automated VMAS on MRIs of CU progressors and non-progressors, there are three important caveats. First, this work used limited sample sizes to estimate ventricular morphometry abnormalities of CU progressors. We will further validate our algorithm in other large brain image cohorts, such as ADNI-2 ([@b0215]), UK Biobank ([@b0405]) and Adolescent Brain Cognitive Development (ABCD) study ([@b0235]). And we will apply VMAS to compare and correlate with other well-known biomarkers like amyloid-status ([@b0475]) and tau PET biomarkers ([@b0035], [@b0175]). Second, due to the age difference in two cohorts, the identified expansive regions across cohorts are not identical. We can observe extended significantly different areas in the elder ADNI cohort. It may indicate that the increased enlargement areas in the elder CU progressor group. The study of ([@b0470]) applied the linear mixed effects model to track the sensitive hippocampal subregion univariate volume differences in CU and AD populations. In future work, to suppress cohort heterogeneity and keep the general deformation subregions, we will explore the linear mixed effects model ([@b0030], [@b0470]) on multivariate morphometry statistics. Third, VMAS integrated RD and mTBM for improved statistical power. The current RD computation relies on surface conformal parameterization and on *iso*-u curves ([@b0445]). Our recent work ([@b0285]) proposed a novel method to compute regularized Wasserstein means. The computed Wasserstein means of surface is a skeleton which carries global shape information. Therefore, the radial distance defined on the Wasserstein means may be more robust and accurate. Our future work will integrate the robust RD estimate method ([@b0285]) into the VMAS. We expect that by combining the new RD statistical method and mTBM, the VMAS may gain more statistical power at detecting localized ventricular anatomical expansions of CU progressors.

5. Conclusion {#s0110}
=============

This work proposed a novel automated ventricular morphometry analysis system. There are several advantages of this system. First, the individual ventricle mask is derived from a common template which reflects common and special ventricular structural variations. Second, it generates a whole connected 3D ventricular shape model which benefits the surface-based morphometric analysis. Finally, it works on an automated pipeline, without subjective interventions during the process. The VMAS was test-retested on two independent cognitively unimpaired cohorts, and showed that ventricular morphometric abnormalities of the CU progressors can be detected prior to imminent progression to clinically significant memory decline, with LV surface statistics presenting higher effect sizes than RV.
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